Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests tislelizumab with chemotherapy and chest radiation for advanced lung cancer

Tests tislelizumab, chemotherapy and chest radiation in adults with extensive small-cell lung cancer.

Key facts

Who runs it
Second Hospital of Shanxi Medical University
Where
Jincheng, Jinzhong, and Taiyuan, ChinaSee the 6 sites
Trial code
Registry title
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
1 Aug 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Tislelizumab
  • Etoposide
  • Carboplatin or Cisplatin
  • Thoracic radiotherapy
Record updated
24 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with extensive-stage small-cell lung cancer who have not yet had treatment for this stage. All get Tislelizumab with chemotherapy and chest radiotherapy.

Age
18 to 80 years old, both ages included.
Sex
Men and women can join.
Disease stage
Extensive-stage small-cell lung cancer, confirmed by tissue or cell tests. At least one tumour of 10 mm or more across that can be measured on imaging.
Earlier treatment
No earlier antitumor treatment for extensive-stage disease. Earlier chemotherapy or radiotherapy for limited-stage disease is allowed if it aimed to remove all of the disease and at least 6 months have passed since it ended. No earlier treatment aimed at the PD-(L)1 pathway.

Main reasons for not taking part

  • Severe lung disease such as pulmonary fibrosis
  • Mental illness, blood diseases, autoimmune diseases, or severe heart, brain, liver or kidney disease
  • Active infection that is not under control
  • Known or suspected allergy to the study drugs or their ingredients
  • Pregnant or breastfeeding women, or women who could become pregnant with a positive pregnancy test

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form
  • Confirmed small cell lung cancer of extensive stage by histology or cytology
  • At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI
  • Within 3 days prior to treatment, an ECOG score of 0 to 1
  • No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC)
  • Expected life span of ≥3 months
  • Good function of vital organs
  • The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up

Who cannot take part

  • Concurrent severe respiratory diseases: such as pulmonary fibrosis
  • Prior use of antitumor treatment targeting the PD-(L)1 pathway
  • Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys
  • Uncontrolled active infections
  • Known or suspected allergies to the study medication and its excipients
  • Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • Jincheng General HospitalJincheng, ChinaContact: Xueqin Li, Dr.Taking people
  • Jinzhong third people's hospitalJinzhong, ChinaContact: Qian Wu, Dr.Taking people
  • Second hospital of Shanxi Medical UniversityTaiyuan, ChinaContact: Gang Jin, Dr.Taking people
  • Shanxi Bethune HospitalTaiyuan, ChinaContact: Huijing Feng, Dr.Taking people
  • Shanxi Hospital of Traditional Chinese MedicineTaiyuan, ChinaContact: Jinyang Bai, Dr.Taking people
  • TISCO General HospitalTaiyuan, ChinaContact: Weihua Jia, Dr.Taking people

About the trial

What the trial wants to find out

This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

The group in the trial

  • ICI+EC/EP+TRTTreatment being tested

    Drug: Tislelizumab Drug: Carboplatin Drug: Etoposide Radiation: Radiation therapy Drug: Cisplatin

    Treatment: Tislelizumab, Etoposide, Carboplatin or Cisplatin, and Thoracic radiotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): an Multicenter, Single Arm Prospective Trial
Plain-language title
Tests tislelizumab with chemotherapy and chest radiation for advanced lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06536868, who can take part
Record updated
24 April 2026